Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
Presentation / Abstract • Phase 2Poster presentation Mon, Jun 1, 2026, 1:30 PM CT
Company profile
Atossa Therapeutics, Inc.
Pipeline1 asset
- (Z)-endoxifenestrogen receptor / oral small molecule SERM/D / Oncology; rare diseasesMetastatic breast cancerPhase 1/2FDA pathway discussions; IND study may proceed reportedUSAdjuvant breast cancerFDA pathway discussionsUSNeoadjuvant breast cancerongoing clinical studies: EVANGELINE and I-SPY2
Latest news11 items
All newsAtossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Results CallResults call Tue, May 19, 2026, 1:00 PM PT